Your browser doesn't support javascript.
loading
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.
Eikelboom, John W; Jolly, Sanjit S; Belley-Cote, Emilie P; Whitlock, Richard P; Rangarajan, Sumathy; Xu, Lizhen; Heenan, Laura; Bangdiwala, Shrikant I; Luz Diaz, Maria; Diaz, Rafael; Yusufali, Afzalhussein; Kumar Sharma, Sanjib; Tarhuni, Wadea M; Hassany, Mohamed; Avezum, Alvaro; Harper, William; Wasserman, Sean; Almas, Aysha; Drapkina, Oxana; Felix, Camilo; Lopes, Renato D; Berwanger, Otavio; Lopez-Jaramillo, Patricio; Anand, Sonia S; Bosch, Jackie; Choudhri, Shurjeel; Farkouh, Michael E; Loeb, Mark; Yusuf, Salim.
Afiliação
  • Eikelboom JW; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: eikelbj@mcmaster.ca.
  • Jolly SS; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Belley-Cote EP; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Whitlock RP; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada; Department of Surgery, McMaster University, Hamilton, ON, Canada.
  • Rangarajan S; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada.
  • Xu L; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada.
  • Heenan L; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada.
  • Bangdiwala SI; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada.
  • Luz Diaz M; Estudios Clínicos Latino América, Instituto Cardiovascular de Rosario, Rosario, Argentina.
  • Diaz R; Estudios Clínicos Latino América, Instituto Cardiovascular de Rosario, Rosario, Argentina.
  • Yusufali A; Hatta Hospital, Dubai Medical College, Dubai Health Authority, Dubai, United Arab Emirates.
  • Kumar Sharma S; BP Koirala Institute of Health Sciences, Dharan, Nepal.
  • Tarhuni WM; Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada; Department of Medicine, Western University, Clinical Skills Building London, ON, Canada; Windsor Cardiac Centre, Windsor, ON, Canada.
  • Hassany M; National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt.
  • Avezum A; International Research Center, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.
  • Harper W; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada.
  • Wasserman S; Wellcome Centre for Infectious Diseases Research in Africa, Institute for Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa; Division of Infectious Diseases and HIV Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa.
  • Almas A; Section of Internal Medicine, Department of Medicine, Aga Khan University, Karachi, Pakistan.
  • Drapkina O; National Medical Research Center for Therapy and Preventive Medicine, Moscow, Russia.
  • Felix C; Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Ecuador.
  • Lopes RD; Division of Cardiology, Duke University Medical Center, Duke Clinical Research Institute, NC, USA.
  • Berwanger O; Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Lopez-Jaramillo P; Masira Research Institute, Medical School, Universidad de Santander, Bucaramanga, Colombia.
  • Anand SS; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.
  • Bosch J; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada; School of Rehabilitation Science, McMaster University, Hamilton, ON, Canada.
  • Choudhri S; Bayer, Medical & Scientific Affairs, Mississauga, ON, Canada.
  • Farkouh ME; Peter Munk Cardiac Centre, University of Toronto, Toronto, ON, Canada.
  • Loeb M; Departments of Pathology and Molecular Medicine and Health Evidence Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
  • Yusuf S; Population Health Research Institute, McMaster University and Hamilton Health Sciences Hamilton, Canada; Department of Surgery, McMaster University, Hamilton, ON, Canada.
Lancet Respir Med ; 10(12): 1169-1177, 2022 12.
Article em En | MEDLINE | ID: mdl-36228641
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rivaroxabana / Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Humans País/Região como assunto: America do norte Idioma: En Revista: Lancet Respir Med Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rivaroxabana / Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Humans País/Região como assunto: America do norte Idioma: En Revista: Lancet Respir Med Ano de publicação: 2022 Tipo de documento: Article